Sonic Healthcare delivered a strong finish to fiscal 2026, with net profit climbing 18.4% to A$608.3 million against the backdrop of 12.7% revenue growth to A$10.9 billion. The outperformance of profit growth relative to revenue growth points to meaningful operational leverage, as the pathology and imaging services provider demonstrably improved its cost structure and operational efficiency across the financial year. This margin expansion is the key takeaway from the results and reflects the company’s ability to leverage its scale while managing its substantial cost base across laboratory networks, imaging centers, and corporate infrastructure spanning multiple geographies.
Underlying EBITDA reached A$1,933 million on a constant currency basis, advancing 11% year on year, while underlying net profit of A$621 million grew 17%. Cash generation from operations strengthened to A$1,405 million, up 8.4%, demonstrating that reported earnings translated into tangible cash inflows for the business. The company benefited from a A$106.7 million gain related to sale and leaseback of property during the year, a transaction structure that appears to have enhanced both reported profitability and cash flow while maintaining operational flexibility across the group’s real estate footprint.
Shareholders will receive a final dividend of 37.8 cents per share, with 22.05 cents fully franked, alongside the earlier interim distribution of 2.3 cents per share. The franked component carries significant weight for Australian tax-resident investors, while the company notes that the unfranked portion qualifies as conduit foreign income, meaning non-resident shareholders face no Australian dividend withholding tax on that component. The company’s Dividend Reinvestment Plan remains suspended, signaling management’s preference for returning capital to shareholders through direct cash payments rather than equity accumulation. This capital return policy, combined with the property transaction executed during the year, demonstrates a board and management focused on rewarding equity holders while maintaining financial flexibility for strategic deployment.
Earnings per share advanced 12.7% to 120.6 cents on a diluted basis, reflecting both the profit growth and a stable share count. Investors should monitor how Sonic maintains its margin gains in the face of potential wage inflation or cost pressures within the pathology and imaging sectors, and whether management can deploy capital through acquisitions or organic investment at returns that justify current valuation levels. The preliminary final report is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Sonic Healthcare Limited (ASX: SHL)
Sonic Healthcare Limited is a global healthcare provider operating the largest private medical laboratory and pathology services in Australia, the United Kingdom, Germany, and Switzerland. The company generates approximately 85% of its revenue from pathology services and is also the second-largest operator of diagnostic imaging services in Australia and the largest operator of medical centers in Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
